Insurance companies dropping prescription drug coverage

Elaine Moore writes,

With the increasing costs of specialized drugs, some insurance companies are refusing to pay for drugs prescribed for off-label conditions …

Health policy analysts caution that the benefits off-label drugs offer in conditions for which other drugs have failed will be seriously compromised by these new insurance regulations.

Furthermore, off-label drugs such as naltrexone, which is relatively inexpensive at less than $100 per month, would be put in the same (unapproved for payment) category as Genetech’s Avastin (bevacizumab), which typically costs $4,400 per month. Avastin is approved for lung and colorectal cancers, but not for brain tumors because of limited evidence validating efficacy despite promising results in patients.

343

Related Posts

Leave a comment